Association of Germline BRCA2 Mutations With the Risk of Pediatric or Adolescent Non–Hodgkin Lymphoma | Pediatric Cancer | JAMA Oncology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.237.138.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
July 25, 2019

Association of Germline BRCA2 Mutations With the Risk of Pediatric or Adolescent Non–Hodgkin Lymphoma

Author Affiliations
  • 1Department of Epidemiology and Cancer Control, St Jude Children’s Research Hospital, Memphis, Tennessee
  • 2Department of Computational Biology, St Jude Children’s Research Hospital, Memphis, Tennessee
  • 3Department of Oncology, St Jude Children’s Research Hospital, Memphis, Tennessee
JAMA Oncol. 2019;5(9):1362-1364. doi:10.1001/jamaoncol.2019.2203

In a previous report from the St Jude Lifetime (SJLIFE) study, BRCA2 (GenBank U43746 .1) was the third most frequently mutated gene (14 occurrences) among 3006 survivors of childhood cancer, with the highest number observed among survivors of lymphoma (7 [1.2%] of 586).1 To further investigate BRCA2 as a potential predisposition gene for pediatric or adolescent lymphoma, we analyzed 794 additional survivors of lymphoma from the SJLIFE study2 and Childhood Cancer Survivor Study3 cohorts, using whole-genome sequencing data.

Participants included 5-year survivors of pediatric or adolescent lymphomas. Germline whole-genome sequencing (30-fold coverage) was performed using DNA extracted from peripheral blood (SJLIFE study) or buccal or saliva samples (Childhood Cancer Survivor Study). This present study was approved by the institutional review board of St Jude Children’s Research Hospital. Study participants provided written informed consent at the time of sample collection.

×